NO20076425L - Fremgangsmater for behandling av drug-resistent cancer - Google Patents

Fremgangsmater for behandling av drug-resistent cancer

Info

Publication number
NO20076425L
NO20076425L NO20076425A NO20076425A NO20076425L NO 20076425 L NO20076425 L NO 20076425L NO 20076425 A NO20076425 A NO 20076425A NO 20076425 A NO20076425 A NO 20076425A NO 20076425 L NO20076425 L NO 20076425L
Authority
NO
Norway
Prior art keywords
compound
resistant cancer
methods
treating drug
tautomer
Prior art date
Application number
NO20076425A
Other languages
English (en)
Inventor
Glenn C Michelson
Vivien W Chan
Carla C Heise
Marion Wiesmann
Timothy D Dawes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20076425L publication Critical patent/NO20076425L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

En fremgangsmåte for behandling av medikamentresistent cancer inkluderer: administrere til en pasient med behov derav, en forbindelse av formel 1, en tautomer av forbindelsen, et salt av forbindelsen, et salt av tautomeren, en blanding derav, eller en farmasøytisk sammensetning omfattende forbindelsen, tautomeren, saltet av forbindelsen, saltet av tautomeren eller blandingen, hvor pasienten er en cancerpasient med medikamentresistent cancer, hvor forbindelsen av formel I er som definert i søknaden.
NO20076425A 2005-05-13 2007-12-13 Fremgangsmater for behandling av drug-resistent cancer NO20076425L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68072205P 2005-05-13 2005-05-13
PCT/US2006/017922 WO2006124413A2 (en) 2005-05-13 2006-05-10 Methods for treating drug resistant cancer

Publications (1)

Publication Number Publication Date
NO20076425L true NO20076425L (no) 2008-01-30

Family

ID=37431829

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076425A NO20076425L (no) 2005-05-13 2007-12-13 Fremgangsmater for behandling av drug-resistent cancer

Country Status (23)

Country Link
US (1) US8299081B2 (no)
EP (1) EP1885187B1 (no)
JP (2) JP5344910B2 (no)
KR (1) KR101319122B1 (no)
CN (1) CN101222850B (no)
AU (1) AU2006247803B2 (no)
BR (1) BRPI0610360A2 (no)
CA (1) CA2608171C (no)
DK (1) DK1885187T3 (no)
ES (1) ES2440799T3 (no)
HK (1) HK1110477A1 (no)
IL (1) IL187327A (no)
MA (1) MA29543B1 (no)
MX (1) MX2007014206A (no)
NO (1) NO20076425L (no)
NZ (1) NZ564144A (no)
PL (1) PL1885187T3 (no)
PT (1) PT1885187E (no)
RU (1) RU2426539C2 (no)
SI (1) SI1885187T1 (no)
TN (1) TNSN07419A1 (no)
WO (1) WO2006124413A2 (no)
ZA (1) ZA200709620B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101423513B (zh) * 2007-10-29 2013-03-27 中国医学科学院药物研究所 胺基嘧啶衍生物、及其制法和药物组合物与用途
DK2149372T3 (da) * 2008-07-31 2014-07-07 Universität Ulm Anvendelse af opioider af metadongruppen til behandling af patienter med resistent cancer
US9095592B2 (en) * 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US9519613B2 (en) * 2009-02-02 2016-12-13 Asurion, Llc Method for integrating applications in an electronic address book
TWI410418B (zh) 2009-04-29 2013-10-01 Ind Tech Res Inst 氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
EP2558082A1 (en) * 2010-04-16 2013-02-20 Novartis AG Combination of organic compounds
KR20140023358A (ko) * 2011-05-19 2014-02-26 노파르티스 아게 선양 낭성 암종의 치료에 사용하기 위한 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
AU2013215251A1 (en) * 2012-01-31 2014-08-14 Novartis Ag Combination of a RTK inhibitor with an anti - estrogen and use thereof for the treatment of cancer
US20150202203A1 (en) 2012-07-11 2015-07-23 Novartis Ag Method of Treating Gastrointestinal Stromal Tumors
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
RU2547999C1 (ru) * 2013-10-28 2015-04-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения аденогенного местно-распространенного рака нижнеампулярного отдела прямой кишки
WO2016123054A2 (en) * 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Kinase drug combinations and methods of use thereof
JP7466308B2 (ja) * 2016-09-20 2024-04-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US580883A (en) * 1897-04-20 Logging-sled
US3663606A (en) 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
DE3248043A1 (de) 1982-12-24 1984-06-28 Bayer Ag, 5090 Leverkusen Fluorogene phosphorsaeureester, verfahren zu deren herstellung sowie verfahren und mittel zum nachweis und zur fluorometrischen bestimmung von phosphaten
US4659657A (en) 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
DE3634066A1 (de) 1986-10-07 1988-04-21 Boehringer Mannheim Gmbh Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPH07121937B2 (ja) 1987-03-18 1995-12-25 大塚製薬株式会社 カルボスチリル誘導体
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
JPH02229165A (ja) 1989-03-02 1990-09-11 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
DE3932953A1 (de) 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5151360A (en) 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
GB9107742D0 (en) 1991-04-11 1991-05-29 Rhone Poulenc Agriculture New compositions of matter
GB9108369D0 (en) 1991-04-18 1991-06-05 Rhone Poulenc Agriculture Compositions of matter
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
EP0584222B1 (en) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5856115A (en) 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
DK0627940T3 (da) 1992-03-05 2003-09-01 Univ Texas Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
CA2143748A1 (en) 1992-09-02 1994-03-17 C. Frank Bennett Oligonucleotide modulation of cell adhesion
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
US5498608A (en) 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
AU5881394A (en) 1994-01-08 1995-08-01 Rhone-Poulenc Agriculture Limited Benzimidazolyl quinoline-3-carboxylate derivatives, intermediates thereto, and their use as herbicides
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
JP2000501736A (ja) 1995-12-12 2000-02-15 メルク エンド カンパニー インコーポレーテッド ロサルタンの新用途
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6010711A (en) 1996-01-26 2000-01-04 University Of Rochester Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
US6111110A (en) 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
AU3850299A (en) 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
US6174912B1 (en) 1998-08-21 2001-01-16 Dupont Pharmaceuticals Company Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
US20030087854A1 (en) 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
JP4707240B2 (ja) 1999-05-05 2011-06-22 アベンティス・フアーマ・リミテッド 細胞接着調節剤としての尿素
KR100298572B1 (ko) 1999-08-19 2001-09-22 박찬구 카바아닐라이드로부터 4-니트로디페닐아민과 4-니트로소디페닐아민의 제조방법
DZ3223A1 (fr) 1999-10-19 2001-04-26 Merck & Co Inc Inhibiteurs de tyrosine kinases
EP1226119B1 (en) 1999-10-19 2005-03-16 MERCK & CO. INC. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2402589C (en) 2000-03-07 2011-02-01 Sanjay Garg Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
WO2002017913A1 (fr) 2000-08-30 2002-03-07 Sankyo Company, Limited Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
AU2001288432A1 (en) 2000-09-01 2002-03-22 Icos Corporation Materials and methods to potentiate cancer treatment
US6756383B2 (en) * 2000-09-01 2004-06-29 Chiron Corporation Heterocyclic derivatives of quinolinone benimidazoles
ATE386736T1 (de) 2000-09-11 2008-03-15 Novartis Vaccines & Diagnostic Verfahren zur herstellung von benzimidazol-2-yl - chinolinonderivaten
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US20030159702A1 (en) 2002-01-21 2003-08-28 Lindell Katarina E.A. Formulation and use manufacture thereof
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
EP1565187A4 (en) 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic CANCER TREATMENT METHODS AND RELATED METHODS
US6774327B1 (en) 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
MXPA06004199A (es) 2003-10-17 2006-06-28 Novo Nordisk As Terapia en combinacion.
BRPI0416143A (pt) 2003-11-07 2007-01-02 Chiron Corp sais farmaceuticamente aceitáveis de compostos de quinolinona tendo propriedades farmacêuticas aperfeiçoadas
JP5019884B2 (ja) * 2004-02-20 2012-09-05 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 炎症プロセスおよび転移プロセスの調節
AU2006208012B2 (en) * 2005-01-27 2011-08-04 Novartis Vaccines And Diagnostics Inc. Treatment of metastasized tumors
EP1885801A1 (en) * 2005-05-18 2008-02-13 M & G Polimeri Italia S.P.A. Polyester composition
AU2007272330A1 (en) 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
KR20090046893A (ko) 2006-07-28 2009-05-11 노파르티스 아게 흑색종에서 치료학적 반응에 대한 조기 지표로서의 흑색종 억제 활성 (ｍｉａ) 단백질의 용도

Also Published As

Publication number Publication date
CN101222850B (zh) 2012-10-03
BRPI0610360A2 (pt) 2010-06-15
MX2007014206A (es) 2008-02-07
SI1885187T1 (sl) 2013-12-31
RU2007145932A (ru) 2009-06-20
AU2006247803B2 (en) 2011-12-22
PL1885187T3 (pl) 2014-03-31
IL187327A0 (en) 2008-04-13
PT1885187E (pt) 2013-12-16
JP2008540543A (ja) 2008-11-20
CN101222850A (zh) 2008-07-16
US20090215793A1 (en) 2009-08-27
EP1885187A4 (en) 2009-05-13
EP1885187B1 (en) 2013-09-25
US8299081B2 (en) 2012-10-30
MA29543B1 (fr) 2008-06-02
NZ564144A (en) 2009-11-27
KR20080033902A (ko) 2008-04-17
WO2006124413A2 (en) 2006-11-23
JP2013173787A (ja) 2013-09-05
DK1885187T3 (da) 2013-12-09
KR101319122B1 (ko) 2013-10-23
ZA200709620B (en) 2008-10-29
RU2426539C2 (ru) 2011-08-20
EP1885187A2 (en) 2008-02-13
CA2608171C (en) 2014-02-04
ES2440799T3 (es) 2014-01-30
IL187327A (en) 2015-05-31
HK1110477A1 (en) 2008-07-18
CA2608171A1 (en) 2006-11-23
TNSN07419A1 (en) 2009-03-17
AU2006247803A1 (en) 2006-11-23
JP5344910B2 (ja) 2013-11-20
WO2006124413A3 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0409198A (pt) derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
MX2009004699A (es) Compuestos de piridinona.
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
EA200700501A1 (ru) Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества
DE602005013793D1 (de) Thiazolderivate mit vap-1-hemmender wirkung
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
BR0315580A (pt) Derivados de metileno uréia
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
ATE391710T1 (de) Substituierte azetidinverbindungen als cyclooxigenase-1-cyclooxygenase-2-inhibitoren und deren herstellung und verwendung als medikament

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application